RESTRICTED AREA
* The information contained on this page is intended for veterinarians or animal health professionals with the ability to prescribe and/or dispense medicines.If you meet these requirements, talk to our sales department.
Ref.: DC 01 680
PERGOSAFE 0,5mg 160 tablets
Pergolide
If you have already registered, log in to GirovetPro
Presentation:
Description
COMPOSITION
Pergolide 0,5 mg
PRESENTATION
160 tablets
SPECIES
Equine
Pergolide 0,5 mg
PRESENTATION
160 tablets
SPECIES
Equine
Indications
Symptomatic treatment of the clinical signs associated with pituitary pars intermedia dysfunction (PPID) (equine Cushing's disease).
Appropriate endocrine laboratory tests, as well as an evaluation of clinical signs, should be performed to establish the diagnosis of PPID.
Appropriate endocrine laboratory tests, as well as an evaluation of clinical signs, should be performed to establish the diagnosis of PPID.
Dose / Application / Administration
Oral administration, once daily.
To facilitate administration, the required daily dose should be placed in a small amount of water and/or mixed with molasses or another sweetener and stirred until dissolved. In this case, the dissolved tablets should be administered using a syringe. The entire amount should be administered immediately.
The tablets should not be crushed.
Starting dose: The starting dose is approximately 2 µg of pergolide/kg (dose range: 1.3 to 2.5 µg/kg; see table below). The maintenance dose should be titrated according to individual response, as determined by monitoring (see below), resulting in an average maintenance dose of 2 µg of pergolide/kg body weight, with a dose range of 0.6 to 10 µg of pergolide/kg body weight. The recommended starting doses are shown below:
Maintenance Dosage
It is anticipated that lifelong treatment will be necessary for this disease.
Most horses respond to therapy and stabilize at an average dose of 2 µg of pergolide/kg body weight. Clinical improvement is expected with pergolide administration within 6 to 12 weeks. Horses may respond clinically to lower or variable doses; therefore, titration to the minimum effective dose for each animal is recommended based on the response to therapy, whether efficacy is observed or signs of intolerance appear. Some horses may require doses up to 10 µg of pergolide/kg body weight per day. In these rare situations, appropriate additional monitoring is recommended.
After the initial diagnosis, repeat endocrine tests to perform titration and monitor treatment at 4- to 6-week intervals until clinical signs stabilize or improve and/or diagnostic tests are performed.
Consult the technical data sheet for more information on dosage.
To facilitate administration, the required daily dose should be placed in a small amount of water and/or mixed with molasses or another sweetener and stirred until dissolved. In this case, the dissolved tablets should be administered using a syringe. The entire amount should be administered immediately.
The tablets should not be crushed.
Starting dose: The starting dose is approximately 2 µg of pergolide/kg (dose range: 1.3 to 2.5 µg/kg; see table below). The maintenance dose should be titrated according to individual response, as determined by monitoring (see below), resulting in an average maintenance dose of 2 µg of pergolide/kg body weight, with a dose range of 0.6 to 10 µg of pergolide/kg body weight. The recommended starting doses are shown below:
Maintenance Dosage
It is anticipated that lifelong treatment will be necessary for this disease.
Most horses respond to therapy and stabilize at an average dose of 2 µg of pergolide/kg body weight. Clinical improvement is expected with pergolide administration within 6 to 12 weeks. Horses may respond clinically to lower or variable doses; therefore, titration to the minimum effective dose for each animal is recommended based on the response to therapy, whether efficacy is observed or signs of intolerance appear. Some horses may require doses up to 10 µg of pergolide/kg body weight per day. In these rare situations, appropriate additional monitoring is recommended.
After the initial diagnosis, repeat endocrine tests to perform titration and monitor treatment at 4- to 6-week intervals until clinical signs stabilize or improve and/or diagnostic tests are performed.
Consult the technical data sheet for more information on dosage.
Composition
Each tablet contains:
Active ingredient:
Pergolide 0.5 mg equivalent to 0.66 mg of pergolide mesylate
Active ingredient:
Pergolide 0.5 mg equivalent to 0.66 mg of pergolide mesylate
Presentation
160 cápsulas de 0.5mg
Laboratory
DECHRA
Leave us your comment